Compare EVCM & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVCM | NVAX |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.3B |
| IPO Year | 2021 | 1996 |
| Metric | EVCM | NVAX |
|---|---|---|
| Price | $9.60 | $9.23 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 9 |
| Target Price | $10.67 | ★ $11.33 |
| AVG Volume (30 Days) | 89.6K | ★ 4.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 145.45 | ★ 309.76 |
| EPS | ★ 0.04 | N/A |
| Revenue | $588,907,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $5.84 | N/A |
| P/E Ratio | $242.00 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $7.66 | $6.20 |
| 52 Week High | $14.41 | $11.85 |
| Indicator | EVCM | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 34.66 | 55.25 |
| Support Level | $9.35 | $9.14 |
| Resistance Level | $12.31 | $10.63 |
| Average True Range (ATR) | 0.84 | 0.61 |
| MACD | -0.21 | 0.18 |
| Stochastic Oscillator | 11.37 | 49.01 |
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. The Company served more than 745,000 customers across three core verticals: EverPro for Home Services; EverHealth for Health Services; and EverWell for Wellness Services. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.